Form 4: Citius Pharmaceuticals Vice Chairman Myron Z. Holubiak Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, reports transactions involving warrants and stock options, including amendments to extend warrant termination dates.
Summary
- Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership.
- The report includes transactions related to warrants to purchase common stock, specifically amendments to extend the termination dates of existing warrants.
- The amendments involved the cancellation of 'old' warrants and the grant of replacement warrants with extended expiration dates.
- Holubiak also holds various stock options with different exercise prices and expiration dates, some of which are fully vested and others that vest over time based on continued service to the company.
- Some options are held by Holubiak's daughter, and he disclaims beneficial ownership of those shares.
Sentiment
Score: 5
Explanation: This is a neutral report on insider trading activity, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 08/13/2018 | Original issue date of warrant that was amended on 08/14/2024. |
| 09/27/2019 | Original issue date of warrant that was amended on 09/25/2024. |
| 07/22/2021 | Options granted on this date vest over three years. |
| 10/11/2021 | Options granted on this date vest over three years. |
| 10/04/2022 | Options granted on this date vest over three years. |
| 10/10/2023 | Options granted on this date vest over three years. |
| 08/14/2024 | Date of warrant amendment and grant of replacement warrant with extended termination date to August 14, 2025. |
| 08/14/2024 | Earliest transaction date reported. |
| 09/25/2024 | Date of warrant amendment and grant of replacement warrant with extended termination date to September 27, 2025. |
| 09/27/2024 | Date of report. |
| 10/01/2025 | Expiration date for options to purchase 26,667 shares at $8.10. |
| 04/05/2025 | Expiration date for warrant to purchase 129,450 shares at $1.42. |
| 08/14/2025 | New expiration date for amended warrant to purchase 784,314 shares at $1.15. |
| 09/27/2025 | New expiration date for amended warrant to purchase 558,597 shares at $0.77. |
| 09/13/2027 | Expiration date for options to purchase 40,000 shares at $3.45. |
| 09/04/2028 | Expiration date for options to purchase 150,000 shares at $1.62. |
| 10/08/2029 | Expiration date for options to purchase 175,000 shares at $0.67. |
| 10/06/2030 | Expiration date for options to purchase 200,000 shares at $1.01. |
| 07/22/2031 | Expiration date for options to purchase 300,000 shares at $2.00 and 10,000 shares at $2.00 (held by daughter). |
| 10/11/2031 | Expiration date for options to purchase 650,000 shares at $2.04 and 15,000 shares at $2.04 (held by daughter). |
| 10/04/2032 | Expiration date for options to purchase 400,000 shares at $1.25. |
| 10/10/2033 | Expiration date for options to purchase 400,000 shares at $0.70. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.